These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23732970)

  • 1. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes.
    Ishøy PL; Knop FK; Vilsbøll T; Glenthøj BY; Ebdrup BH
    Am J Psychiatry; 2013 Jun; 170(6):681-2. PubMed ID: 23732970
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
    Lane W; Weinrib S; Rappaport J
    Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.
    Varanasi A; Patel P; Makdissi A; Dhindsa S; Chaudhuri A; Dandona P
    Endocr Pract; 2012; 18(2):140-5. PubMed ID: 21856595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
    Svensson CK; Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Koyuncu K; Schjerning O; Nielsen J; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
    Acta Psychiatr Scand; 2019 Jan; 139(1):26-36. PubMed ID: 30374965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 agonists.
    Padwal R
    BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
    [No Abstract]   [Full Text] [Related]  

  • 7. Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
    Elkhenini H; New JP; Summers LK; Syed AA
    Eur J Intern Med; 2014 Mar; 25(3):e38-9. PubMed ID: 24412647
    [No Abstract]   [Full Text] [Related]  

  • 8. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
    Imamura S; Hirai K; Hirai A
    Tohoku J Exp Med; 2013 Sep; 231(1):57-61. PubMed ID: 24064677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
    Ottney A
    Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.
    Holst JJ; Seino Y
    Diabetes Res Clin Pract; 2009 Jul; 85(1):1-3. PubMed ID: 19299027
    [No Abstract]   [Full Text] [Related]  

  • 12. Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.
    Lindamood CA; Taylor JR
    Clin Ther; 2015 Mar; 37(3):483-93. PubMed ID: 25659912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can GLP-1 preparations be used in children and adolescents with diabetes mellitus?
    Shehadeh N; Daich E; Zuckerman-Levin N
    Pediatr Endocrinol Rev; 2014 Mar; 11(3):324-7. PubMed ID: 24716398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
    Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
    Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
    Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
    Trujillo JM; Nuffer W
    Ann Pharmacother; 2014 Nov; 48(11):1494-501. PubMed ID: 25136065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
    Santilli F; Simeone PG; Guagnano MT; Leo M; Maccarone MT; Di Castelnuovo A; Sborgia C; Bonadonna RC; Angelucci E; Federico V; Cianfarani S; Manzoli L; Davì G; Tartaro A; Consoli A
    Diabetes Care; 2017 Nov; 40(11):1556-1564. PubMed ID: 28912305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
    Madsbad S
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):463-77. PubMed ID: 19748064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    Thompson AM; Trujillo JM
    Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
    J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.